Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells
出版年份 2021 全文链接
标题
Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells
作者
关键词
Cediranib, Glioblastoma, VEGF family, Therapeutic sensitization
出版物
LIFE SCIENCES
Volume 287, Issue -, Pages 120100
出版商
Elsevier BV
发表日期
2021-10-27
DOI
10.1016/j.lfs.2021.120100
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
- (2019) Ruben S. A. Goedegebuure et al. Frontiers in Immunology
- The unique invasiveness of glioblastoma and possible drug targets on extracellular matrix
- (2019) Adam Hatoum et al. Cancer Management and Research
- The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells
- (2019) Majid Momeny et al. CELLULAR ONCOLOGY
- Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
- (2019) Fengzhi Li et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Selected by gene co-expression network and molecular docking analyses, ENMD-2076 is highly effective in glioblastoma-bearing rats
- (2019) Sheng Zhong et al. Aging-US
- Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
- (2019) Jun-Hai Tang et al. Cancer Communications
- Diversity and functional evolution of the plasminogen activator system
- (2018) Rishi Kumar Jaiswal et al. BIOMEDICINE & PHARMACOTHERAPY
- Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial
- (2018) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
- (2018) Signe R Michaelsen et al. NEURO-ONCOLOGY
- MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells
- (2018) Sarmistha Talukdar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cell death-based treatment of glioblastoma
- (2018) Simone Fulda Cell Death & Disease
- Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
- (2018) Shabierjiang JIAPAER et al. NEUROLOGIA MEDICO-CHIRURGICA
- The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells
- (2017) Maria Grazia Atzori et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells
- (2017) Majid Momeny et al. Scientific Reports
- Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma
- (2016) C. Kurokawa et al. JOURNAL OF NEURO-ONCOLOGY
- Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo
- (2016) Emese Szabo et al. NEURO-ONCOLOGY
- The Unexpected Roles of Aurora A Kinase in Gliobastoma Recurrences
- (2016) Estelle Willems et al. Targeted Oncology
- Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)
- (2016) Joleen M. Hubbard et al. Targeted Oncology
- Survivin and gliomas: A literature review
- (2016) Rosilin Kotakkathu Varughese et al. Oncology Letters
- Mechanisms regulating glioma invasion
- (2015) Ivy Paw et al. CANCER LETTERS
- Lessons From Anti–Vascular Endothelial Growth Factor and Anti–Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma
- (2015) Christine Lu-Emerson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sensitization of Glioblastoma Cells to Irradiation by Modulating the Glucose Metabolism
- (2015) H. Shen et al. MOLECULAR CANCER THERAPEUTICS
- Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines
- (2015) Majid Momeny et al. Oncotarget
- Small-Molecule XIAP Inhibitors Enhance γ-Irradiation-Induced Apoptosis in Glioblastoma
- (2015) Sri Hari Krishna Vellanki et al. NEOPLASIA
- Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors
- (2014) David S. Hong et al. CANCER
- Epidemiologic and Molecular Prognostic Review of Glioblastoma
- (2014) J. P. Thakkar et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Role of AKT signaling in DNA repair and clinical response to cancer therapy
- (2014) Q. Liu et al. NEURO-ONCOLOGY
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: Implications for stem cell mitosis and centrosome dynamics
- (2014) Mariella Mannino et al. Stem Cell Research
- Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance
- (2014) P Dahan et al. Cell Death & Disease
- Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis
- (2014) Daniela Annibali et al. Nature Communications
- Invasion as target for therapy of glioblastoma multiforme
- (2013) Anne Vehlow et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies
- (2013) Jane Kendrew et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
- (2013) E. Galanis et al. CLINICAL CANCER RESEARCH
- Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
- (2013) A. Jahangiri et al. CLINICAL CANCER RESEARCH
- Glioblastoma Resistance to Anti-VEGF Therapy: Has the Challenge Been MET?
- (2013) J. H. McCarty CLINICAL CANCER RESEARCH
- Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)
- (2013) Daniel Castellano et al. EUROPEAN JOURNAL OF CANCER
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
- (2013) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Review: Molecular mechanism of microglia stimulated glioblastoma invasion
- (2013) Salvatore J. Coniglio et al. MATRIX BIOLOGY
- Akt and c-Myc Induce Stem-Cell Markers in Mature Primary p53−/− Astrocytes and Render These Cells Gliomagenic in the Brain of Immunocompetent Mice
- (2013) Josefine Radke et al. PLoS One
- Inhibitor of Apoptosis (IAP) Proteins-Modulators of Cell Death and Inflammation
- (2013) J. Silke et al. Cold Spring Harbor Perspectives in Biology
- Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma
- (2012) Ravi S. Narayan et al. CURRENT PHARMACEUTICAL DESIGN
- Therapeutic targeting of VEGF in the treatment of glioblastoma
- (2012) Lizbeth Robles Irizarry et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Sensitization of Glioma Cells by X-Linked Inhibitor of Apoptosis Protein Knockdown
- (2012) Patricia L.C. Lopez et al. ONCOLOGY
- The Role of Bcl-2 Family Proteins in Therapy Responses of Malignant Astrocytic Gliomas: Bcl2L12 and Beyond
- (2012) Fotini M. Kouri et al. TheScientificWorldJOURNAL
- Myc proteins in brain tumor development and maintenance
- (2012) Fredrik J. Swartling UPSALA JOURNAL OF MEDICAL SCIENCES
- Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3-kinase/Akt pathway during anti-angiogenesis therapy
- (2011) Yu Wei Zhao et al. CANCER SCIENCE
- Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells
- (2011) JunYu Wang et al. JOURNAL OF NEURO-ONCOLOGY
- Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor
- (2011) Hari Raghu et al. Molecular Cancer
- Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family
- (2011) S. R. Brave et al. MOLECULAR CANCER THERAPEUTICS
- PI3K/AKT/mTOR Pathway in Angiogenesis
- (2011) Jayashree Karar et al. Frontiers in Molecular Neuroscience
- Autocrine regulation of glioblastoma cell-cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay
- (2010) Petra Knizetova et al. CELL CYCLE
- Survivin Is a Potential Mediator of Prostate Cancer Metastasis
- (2010) Min Zhang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiation Resistance in Glioma Cells Determined by DNA Damage Repair Activity of Ape1/Ref-1
- (2010) Mamta D. NAIDU et al. JOURNAL OF RADIATION RESEARCH
- Glioblastoma stem-like cells give rise to tumour endothelium
- (2010) Rong Wang et al. NATURE
- Standard Therapy for Glioblastoma— A Review of Where We Are
- (2010) Ryo NISHIKAWA NEUROLOGIA MEDICO-CHIRURGICA
- Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma
- (2009) Jörg Dietrich et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme
- (2009) M. H. Cohen et al. ONCOLOGIST
- Increased Survivin Expression Confers Chemoresistance to Tumor-Associated Endothelial Cells
- (2008) Jenilyn J. Virrey et al. AMERICAN JOURNAL OF PATHOLOGY
- Urokinase directly activates matrix metalloproteinases-9: A potential role in glioblastoma invasion
- (2008) Yunge Zhao et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition
- (2008) Alexandre Bozec et al. EUROPEAN JOURNAL OF CANCER
- Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
- (2008) J. Ma et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
- Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin
- (2008) Tomoya Kitamura et al. NATURE CELL BIOLOGY
- Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM
- (2008) Rose Du et al. NEURO-ONCOLOGY
- Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins
- (2008) K E Tagscherer et al. ONCOGENE
- Apoptosis: controlled demolition at the cellular level
- (2007) Rebecca C. Taylor et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started